Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Domestic product sales decreased due to the negative impact of the drug price revision, the end of the co-promotion agreement for Forxiga Tablets, and intensifying competition for Opdivo. Profit increased, however, owing to market penetration by Qinlock and Lonvimza, higher royalty income, lower expenses following the end of the co-promotion agreement, a decline in research and development expenses following the previous period's increase, and greater expense efficiency.
No applicable items
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥232,504 million (YoY -9.6%) |
| Operating profit | ¥57,907 million (YoY +11.2%) |
| Ordinary income | ¥58,418 million (YoY +12.0%) |
| Profit attributable to owners of the parent | ¥44,930 million (YoY +12.1%) |
| Net income per share | ¥95.60 |
| Equity ratio | End of the current fiscal period 80.2 / End of previous period 76.9 |
| Total assets | ¥1,091,374 million |
| Net assets | ¥881,557 million |
| Cash flows from operating activities | ¥50,298 million |
| Cash flows from investing activities | ¥1,021 million |
| Cash flows from financing activities | ¥-30,027 million |
| Cash and cash equivalents at end of period | ¥258,178 million |
| Full-year earnings forecast | Net Sales ¥455,000 million (YoY -11.8%) / Operating profit ¥94,000 million (YoY +1.9%) / Ordinary income ¥94,000 million (YoY +1.5%) / Net income ¥71,000 million (YoY +1.8%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥80 → ¥80（0.0%） |
| Depreciation and amortization | ¥18,054 million |
| Disclosure regarding the going concern assumption | No applicable items |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement Not disclosed |
| Changes in the scope of consolidation | No material changes (the number and names of newly consolidated and excluded companies are Not disclosed) |
| Material subsequent events | On 8 October 2026, the Company entered into a licensing agreement with US-based Biohaven for the exclusive development and commercialization of BHV-1300, BHV-1310 and BHV-1320 in Japan, South Korea, Taiwan and the ASEAN countries. The Company will pay an upfront fee of USD 80 million, milestone payments of up to USD 20 million, and royalties based on future sales. The impact on results for the fiscal year ending March 2027 is expected to be minor. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 498,692,800 |
| Treasury Shares at Period-End | 28,585,852 |
| Factors Behind Changes in Business Performance | Domestic product sales decreased due to the negative impact of the drug price revision, the end of the co-promotion agreement for Forxiga Tablets, and intensifying competition for Opdivo. Profit increased, however, owing to market penetration by Qinlock and Lonvimza, higher royalty income, lower expenses following the end of the co-promotion agreement, a decline in research and development expenses following the previous period's increase, and greater expense efficiency. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue decreased due to the negative impact of the drug price revision, the loss of revenue recognition following the end of the co-promotion agreement for Forxiga Tablets, and intensifying competition for Opdivo. Profit increased, however, owing to market penetration by Qinlock and Lonvimza, higher royalty income, lower co-promotion expenses related to Forxiga Tablets, a decline in research and development expenses following the previous period's increase, and greater expense efficiency.